SCHEMBL2701722

SCHEMBL2701722

CN(C)C(=O)c1ccc(-c2ccc(B(O)O)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.53
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MGLL Q99685 1/20 0.47
TRPV1 Q8NER1 2/20 0.46
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
CSNK2A1 P68400 1/20 0.43
MAPT P10636 1/20 0.43
LRRK2 Q5S007 1/20 0.42
NCOA1 Q15788 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL134473 0.94 ALDH1A1 (0.55) ERN1ALDH1A1HPGDSMN1; SMN2CA1
SCHEMBL10626283 0.85 ALDH1A1 (0.64) ERN1ALDH1A1HPGDSMN1; SMN2MMP2
SCHEMBL12663198 0.84 ALDH1A1 (0.46) ERN1ALDH1A1HPGDSMN1; SMN2CA1
SCHEMBL257886 0.84 HPGD (0.76) ALDH1A1HPGDSMN1; SMN2CA1CA2
SCHEMBL1081442 0.80 CA2 (0.43) ALDH1A1HPGDSMN1; SMN2CA1CA2
SCHEMBL1004649 0.78 ALDH1A1 (0.73) ERN1ALDH1A1HPGDSMN1; SMN2MMP2
SCHEMBL2047793 0.78 HPGD (0.63) ERN1ALDH1A1HPGDSMN1; SMN2CYP1A2
SCHEMBL5937241 0.78 CSNK2A1 (0.62) ERN1ALDH1A1HPGDSMN1; SMN2MMP2
SCHEMBL26680622 0.78 HSD17B1 (0.59) ERN1ALDH1A1HPGDSMN1; SMN2MMP2
SCHEMBL16574187 0.78 ALDH1A1 (0.55) ERN1ALDH1A1HPGDSMN1; SMN2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569331-B2 Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds ARQULE, INC. (US) 2013-10-29 US disclosed
WO-2012061342-A2 SUBSTITUTED BENZO-IMIDAZO-PYRIDO-DIAZEPINE COMPOUNDS ARQULE, INC. (US) 2012-05-10 WO disclosed
US-20120108574-A1 Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds ARQULE, INC. (US) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108574-A1 Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds BRD4, BRPF3, BRD3 ERN1 4309/4885ALDH1A1 1178/4885HPGD 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.